<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS108874</article-id>
<article-id pub-id-type="doi">10.1101/2020.12.18.423507</article-id>
<article-id pub-id-type="archive">PPR255706</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>SARS-CoV-2 escapes CD8 T cell surveillance via mutations in MHC-I restricted epitopes</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Agerer</surname>
<given-names>Benedikt</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Koblischke</surname>
<given-names>Maximilian</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Gudipati</surname>
<given-names>Venugopal</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Smyth</surname>
<given-names>Mark</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Popa</surname>
<given-names>Alexandra</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Genger</surname>
<given-names>Jakob-Wendelin</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Endler</surname>
<given-names>Lukas</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Florian</surname>
<given-names>David M.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mühlgrabner</surname>
<given-names>Vanessa</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lercher</surname>
<given-names>Alexander</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gattinger</surname>
<given-names>Pia</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Torralba-Gombau</surname>
<given-names>Ricard</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Penz</surname>
<given-names>Thomas</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fae</surname>
<given-names>Ingrid</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wenda</surname>
<given-names>Sabine</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Traungott</surname>
<given-names>Marianna</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Walder</surname>
<given-names>Gernot</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fischer</surname>
<given-names>Gottfried</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hoepler</surname>
<given-names>Wolfgang</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pawelka</surname>
<given-names>Erich</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zoufaly</surname>
<given-names>Alexander</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Valenta</surname>
<given-names>Rudolf</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bock</surname>
<given-names>Christoph</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Huppa</surname>
<given-names>Johannes B.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Aberle</surname>
<given-names>Judith H.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Bergthaler</surname>
<given-names>Andreas</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria</aff>
<aff id="A2">
<label>2</label>Center for Virology, Medical University of Vienna, Vienna, Austria</aff>
<aff id="A3">
<label>3</label>Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria</aff>
<aff id="A4">
<label>4</label>Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria</aff>
<aff id="A5">
<label>5</label>Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria</aff>
<aff id="A6">
<label>6</label>Department of Medicine IV, Kaiser Franz Josef Hospital, Vienna, Austria</aff>
<aff id="A7">
<label>7</label>Division of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria</aff>
<aff id="A8">
<label>8</label>Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria</aff>
<author-notes>
<corresp id="CR1">
<label>*</label>Correspondence to: A.B. <email>abergthaler@cemm.oeaw.ac.at</email>.</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>24</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="preprint">
<day>20</day>
<month>12</month>
<year>2020</year>
</pub-date>
<permissions>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">CC BY-NC 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">CD8+ T cell immunity to SARS-CoV-2 has been implicated in COVID-19 severity and virus control, though direct evidence has been lacking so far. Here, we identified non-synonymous mutations in MHC-I restricted CD8+ T cell epitopes after deep sequencing of 747 SARS-CoV-2 virus isolates. Mutant peptides exhibited diminished or abrogated MHC-I binding, which was associated with a loss of recognition and functional responses by CD8+ T cells isolated from HLA-matched COVID-19 patients. Our findings highlight the capacity of SARS-CoV-2 to subvert CD8+ T cell surveillance through escape mutations in MHCI-restricted viral epitopes. This provides evolutionary evidence for CD8+ T cell immunity controlling SARS-CoV-2 with consequences for COVID-19 vaccine design.</p>
</abstract>
</article-meta>
</front>
<body>
<p id="P2">SARS-CoV-2 infection elicits broad activation of the innate and adaptive arm of immunity (<xref ref-type="bibr" rid="R3">Le Bert et al., 2020</xref>; <xref ref-type="bibr" rid="R20">Mathew et al., 2020</xref>; <xref ref-type="bibr" rid="R32">Vabret et al., 2020</xref>; <xref ref-type="bibr" rid="R33">Zhang et al., 2020a</xref>). Cytotoxic CD8+ T-Lymphocyte (CTL) responses have been described in great detail in SARS-CoV-2 – infected patients (<xref ref-type="bibr" rid="R3">Le Bert et al., 2020</xref>; <xref ref-type="bibr" rid="R5">Braun et al., 2020</xref>; <xref ref-type="bibr" rid="R8">Dan et al., 2020</xref>; <xref ref-type="bibr" rid="R15">Grifoni et al., 2020a</xref>; <xref ref-type="bibr" rid="R20">Mathew et al., 2020</xref>; <xref ref-type="bibr" rid="R28">Schulien et al., 2020</xref>; <xref ref-type="bibr" rid="R29">Sekine et al., 2020</xref>). Numerous human leucocyte antigen (HLA)-restricted CTL epitopes have been characterized for SARS-CoV-2 (<xref ref-type="bibr" rid="R3">Le Bert et al., 2020</xref>; <xref ref-type="bibr" rid="R16">Grifoni et al., 2020b</xref>; <xref ref-type="bibr" rid="R21">Nelde et al., 2020</xref>; <xref ref-type="bibr" rid="R24">Poran et al., 2020</xref>; <xref ref-type="bibr" rid="R30">Shomuradova et al., 2020</xref>), but whether and how CTLs contribute to protective immunity remains unclear.</p>
<p id="P3">CTLs kill infected cells upon recognition of viral peptides as they are displayed on the cell surface in the context of the products of the class I major histocompatibility complex (MHC-I). CTLs play an essential role in conferring immune memory and protection against viral pathogens (<xref ref-type="bibr" rid="R12">Goulder and Watkins, 2008</xref>; <xref ref-type="bibr" rid="R27">Schmitz et al., 1999</xref>; <xref ref-type="bibr" rid="R31">Thimme et al., 2003</xref>). Compelling evolutionary evidence for CTL-mediated control of RNA viruses like HIV and HCV is provided by mutations occurring in viral epitopes which directly interfere with MHC-I restricted T cell antigen recognition and killing by CTLs (<xref ref-type="bibr" rid="R7">Cox et al., 2005</xref>; <xref ref-type="bibr" rid="R9">Deng et al., 2015</xref>; <xref ref-type="bibr" rid="R14">Goulder et al., 2001</xref>; <xref ref-type="bibr" rid="R22">Pircher et al., 1990</xref>). The extent to which SARS-CoV-2 mutations may upend the presentation of virus-derived peptides via MHC-I remains to be identified.</p>
<p id="P4">To assess the impact of CTLs on the control of SARS-CoV-2, we performed deep viral genome sequencing (&gt; 20.000X coverage (<xref ref-type="supplementary-material" rid="SD2">Fig. S1A</xref>) and bioinformatic analysis on 747 SARS-CoV-2 patient samples (<xref ref-type="bibr" rid="R23">Popa et al., 2020</xref>). We focused on 27 CTL epitopes, which were experimentally shown to be presented by the common subtype HLA-A*02:01 (allele frequency 0.29 in Austria) as well as by the minor subtype HLA-B*40:01 (allele frequency 0.03-0.05 in Austria) (<xref ref-type="bibr" rid="R11">Gonzalez-Galarza et al., 2019</xref>). There, we detected 197 non-synonymous mutations present at frequencies of ≥ 0.02 in 233 samples (<xref ref-type="fig" rid="F1">Fig. 1A-B</xref>) (<xref ref-type="bibr" rid="R3">Le Bert et al., 2020</xref>; <xref ref-type="bibr" rid="R16">Grifoni et al., 2020b</xref>; <xref ref-type="bibr" rid="R24">Poran et al., 2020</xref>; <xref ref-type="bibr" rid="R30">Shomuradova et al., 2020</xref>). Of these 197 variants, 33 were found at frequencies between 0.1 to 0.5. Notably, 9 variants were fixed and found in 53 different patient samples (<xref ref-type="supplementary-material" rid="SD1">Table S1</xref>). Due to overlaps in some epitopes, these 197 mutations result in 207 different epitope variants. 27 of these mutations were localized to anchor residues, and 14 mutations affected auxiliary residues, which are both integral to MHC-I peptide loading (<xref ref-type="supplementary-material" rid="SD2">Fig. S1B</xref>). Prediction of the binding strength of the wildtype and mutant peptides to HLA-A*02:01 and HLA-B*40:01 via netMHCpan v4.1 (<xref ref-type="bibr" rid="R25">Reynisson et al., 2020</xref>) revealed weaker peptide binding to MHC-I, as indicated by an increase of netMHCpan ranks (<xref ref-type="fig" rid="F1">Fig. 1A</xref> and <xref ref-type="supplementary-material" rid="SD2">S1C-F</xref>). For many of the investigated CTL epitopes, we detected multiple variants that independently emerged in different SARS-CoV-2 infected individuals (<xref ref-type="fig" rid="F1">Fig. 1A</xref>). To corroborate these findings from low-frequent mutations in our deep sequencing dataset, we analyzed fixed mutations in &gt;145.000 available global SARS-CoV-2 sequences from the public database GISAID (<xref ref-type="bibr" rid="R10">Elbe and Buckland-Merrett, 2017</xref>). Mutations were observed in 0.0000689 - 7.336% epitope sequences (mean = 0.005106) (<xref ref-type="fig" rid="F1">Fig. 1C</xref>). We found 10 to 11717 viral genome sequences with a non-synonymous mutation for each of the investigated 27 CTL epitopes (mean = 807.05). Importantly, we found fixed variants in GISAID that were also identified in our low-frequency analysis, highlighting the relevance of individual low-frequency mutations (<xref ref-type="fig" rid="F1">Fig. 1D</xref>, S1G-S1I). An alanine to valine mutation within the reported LALLLLDRL epitope (underlined) at nucleotide position 28932 was found in 7.32% (11693/159720) of the analyzed sequences (<xref ref-type="bibr" rid="R28">Schulien et al., 2020</xref>). First detected in June 2020, this variant is now (12.11.2020) not only one of the mutations defining the 20A. EU1 subclade (<xref ref-type="supplementary-material" rid="SD2">Fig. S1J-K</xref>) (<xref ref-type="bibr" rid="R18">Hodcroft et al., 2020</xref>), but it has also been identified in other virus isolates (<xref ref-type="supplementary-material" rid="SD2">Fig. S1J</xref>). Importantly, this mutation had already been detected at low frequency in 7 of our samples collected between March and April 2020, again suggesting independent emergence of the same mutation in multiple individuals (<xref ref-type="supplementary-material" rid="SD2">Fig. S1I</xref>).</p>
<p id="P5">To examine the time dynamics of low-frequency epitope mutations in patients, we utilized serially-sampled viral genomes from COVID-19 patients. We observed that mutations in viral epitopes arising later in infection (<xref ref-type="fig" rid="F1">Fig. 1F</xref>) hinting at CTL-mediated selection pressure mounted over time. Based on our analysis of low-frequency and fixed mutations, we selected 11 wildtype and 17 corresponding mutant peptides with predicted decreased HLA-binding strength for further biophysical and functional analysis (<xref ref-type="supplementary-material" rid="SD2">Table S2</xref>).</p>
<p id="P6">We next employed cell-free differential scanning fluorimetry as a means to compare the capacity of SARS-CoV-2-derived peptides and their non-synonymous mutants to stabilize the structure of recombinant HLA-A*02:01 or HLA-B*40:01 proteins as a direct indicator of MHC-I-peptide binding (<xref ref-type="fig" rid="F2">Fig. 2A-E</xref>, S2A-I) (<xref ref-type="bibr" rid="R4">Blaha et al., 2019</xref>). For 9 of the 11 wildtype peptides we observed binding to HLA-A*02:01 or HLA-B*40:01, suggesting that these peptides could potentially be presented by the respective HLA allele. As shown in <xref ref-type="supplementary-material" rid="SD2">Fig. S2A</xref>, the minima of the curve specify the melting temperature (T<sub>m</sub>) of the HLA-peptide complexes. T<sub>m</sub> values well above 37°C indicate strong peptide binding to MHC-I at physiological temperatures, whereas values around 37°C correlate only with weak and below 36°C with absent binding. In total 11 analyzed mutants exhibited decreased stabilizing capacity towards MHC-I (<xref ref-type="fig" rid="F2">Fig. 2A-E</xref>, S2D-S2H). The HLA-B*40:01 – restricted MEVTPSGTWL peptide featured specific binding to recombinant HLA-B*40:01 but not to HLA-A*02:01 (<xref ref-type="bibr" rid="R3">Le Bert et al., 2020</xref>) (<xref ref-type="fig" rid="F2">Fig. 2C</xref>, S2I). An example for a weak binder is the mutant variant YFQPRTFLL (instead of YLQPRTFLL), whereas LFFNKVTLA (instead of LLFNKVTLA) represents a non-binder for HLA-A*02:01 (<xref ref-type="fig" rid="F2">Fig. 2A</xref>, D). Of note, we did not observe binding of neither wildtype nor mutant peptides for the predicted CTL epitope LALLLLDRL (<xref ref-type="supplementary-material" rid="SD2">Fig. S2J</xref>).</p>
<p id="P7">To further corroborate these results, we generated peptide-loaded HLA-A*02:01 and HLAB*40:01 I tetramers presenting wildtype and mutant peptides as a means to identify cognate CD8+ T-cells from expanded PBMCs of HLA-matched COVID-19 patients (<xref ref-type="fig" rid="F3">Fig. 3A</xref>). As shown in <xref ref-type="fig" rid="F2">Fig. 2F</xref>, tetramers loaded with mutant peptides stain cognate T cells in a TCR-dependent fashion when kept at 4°C. However, when tetramers were incubated at 37°C prior to their use, T cell staining was abrogated, most likely due to peptide loss and structural disintegration of MHC-I. Taken together, these results imply that mutations found in SARSCoV-2 isolates promote immune escape from HLA-dependent recognition by CTLs.</p>
<p id="P8">Next, we investigated peptide-specific CD8+ T-cell responses in PBMCs isolated from HLA-A*02:01 or HLA-B*40:01 positive COVID-19 patients (<xref ref-type="fig" rid="F3">Fig. 3A</xref>, <xref ref-type="supplementary-material" rid="SD2">Table S3</xref>, <xref ref-type="supplementary-material" rid="SD2">Table S4</xref>). To this end HLA-matched PBMCs from COVID-19 patients were stimulated with peptides and cultured for 10-12 days followed by tetramer staining (<xref ref-type="fig" rid="F3">Fig. 3B</xref>). This allowed us to confirm the wildtype peptides as bona-fide T-cell epitopes in SARS-CoV-2. We further corroborated virus-specific CTL responses by intracellular cytokine staining for IFNγ after peptide-mediated re-stimulation (<xref ref-type="supplementary-material" rid="SD2">Fig. S3A, B</xref>). To investigate the extent to which identified mutations in viral epitopes affected T cell proliferation, we stained expanded PBMCs with wildtype peptide-loaded HLA tetramers. We found fewer tetramer-positive CTLs in PBMCs expanded in the presence of mutant peptides, indicating that stimulation with mutant peptides significantly reduces immunogenicity (<xref ref-type="fig" rid="F3">Fig. 3C-F</xref>). Consistent with the tetramer data, intracellular cytokine staining (ICS) for IFNγ revealed significantly diminished CTL responses to mutant peptide as compared to the corresponding wildtype peptides (<xref ref-type="fig" rid="F3">Fig. 3G-J</xref>). We observed markedly diminished CTL responses to several mutant peptides both presented in the context of HLAA:02*01 and HLA-B:40*01. This was further supported by peptide titration experiments involving wildtype peptides and their mutant counterparts for T-cell stimulation (<xref ref-type="supplementary-material" rid="SD2">Fig. S3C</xref>). To complement intracellular cytokine measurements, we also carried out <italic>ex vivo</italic> ELISpot assays after stimulating PBMCs with wildtype or mutant peptides without extended expansion. These experiments confirmed that stimulation with mutant peptides resulted in significantly fewer cytokine-producing cells than with wildtype peptides (<xref ref-type="fig" rid="F3">Fig. 3K</xref>, <xref ref-type="supplementary-material" rid="SD2">S3D</xref>).</p>
<p id="P9">Taken together, our data indicate that SARS-CoV-2 may evade CTL surveillance through mutations in viral epitopes which lead to reduced peptide MHC-I binding. Deep SARS-CoV-2 genome sequencing results afford a valuable additional perspective that complements insights gained from numerous studies on SARS-CoV-2-specific T cell responses (<xref ref-type="bibr" rid="R2">Altmann and Boyton, 2020</xref>). Our data does not rule out that altered residues facing the cognate T cell receptor may give rise to the emergence of CTL neoepitopes.</p>
<p id="P10">Viruses employ numerous strategies to evade CD8+ T cell immune responses (<xref ref-type="bibr" rid="R1">Alcami and Koszinowski, 2000</xref>; <xref ref-type="bibr" rid="R13">Goulder and Watkins, 2004</xref>; <xref ref-type="bibr" rid="R17">Hansen and Bouvier, 2009</xref>). The SARS-CoV-2 encoded ORF8 protein is hypothesized to downregulate the surface expression of MHC-I molecules (<xref ref-type="bibr" rid="R34">Zhang et al., 2020b</xref>), but we still lack a comprehensive understanding of the intrinsic capabilities of SARS-CoV-2 for immune evasion. Our study indicates that CD8+ T cells may shape the evolution of the pandemic SARS-CoV-2 virus. The majority of non-synonymous mutations found in the validated CTL escapes had not reached fixation, i.e. were present at frequencies between 0.02 and 0.42 (<xref ref-type="fig" rid="F1">Fig. 1B</xref>). This could be explained by the rather short infection times of SARS-CoV-2 compared to HIV or HCV. It may also reflect on the degree to which polymorphic HLA expression affects viral spreading within the human population, as selection pressures on CTL epitopes appear to be specific for each infected individual. While it is still unclear whether these mutations may impose any fitness cost on the virus, we identified one non-synonymous mutation in the reported CTL epitope LALLLLDL that is found in an increasing number of circulating SARS-CoV-2 viruses worldwide (<xref ref-type="bibr" rid="R18">Hodcroft et al., 2020</xref>).</p>
<p id="P11">A large number of CTL epitopes for SARS-COV-2 has been described (<xref ref-type="bibr" rid="R2">Altmann and Boyton, 2020</xref>). Natural CTL responses in infected individuals seem to be limited to subsets of epitopes, which raises the question whether and how mutations in single epitopes affect virus control. This may be of particular importance for SARS-CoV-2 subunit vaccines that induce responses against a limited number of epitopes (<xref ref-type="bibr" rid="R6">Corbett et al., 2020</xref>; <xref ref-type="bibr" rid="R19">Liu et al., 2020</xref>; <xref ref-type="bibr" rid="R26">Sahin et al., 2020</xref>). In summary, our results highlight the capacity of SARS-CoV-2 to evade adaptive immune responses and provide further evidence for the impact of endogenous CTL responses and their participation in conferring protection in natural and vaccine-induced immunity.</p>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Table S1</label>
<media xlink:href="EMS108874-supplement-Table_S1.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="N66396" position="anchor"/>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD2">
<label>Supplementary Materials</label>
<media xlink:href="EMS108874-supplement-Supplementary_Materials.pdf" mimetype="application" mime-subtype="pdf" id="N66405" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S1">
<title>Acknowledgments</title>
<p>We thank the Biomedical Sequencing Facility at CeMM for assistance with next-generation sequencing. We thank Ursula Sinzinger, Amelie Popowitsch and Regina Sommer for excellent technical assistance; We thank Lukas Flatz, Giulio Superti-Furga, Dietmar Zehn and Rolf Zinkernagel for valuable feedback and comments.</p>
<p>BA was supported by the Austrian Science Fund (FWF) DK W1212. MS and AL were supported by DOC fellowships of the Austrian Academy of Sciences (No. 24813, No. 24158 and No. 24955 respectively). VG, VM and JBH received support from the Vienna Science and Technology Fund (WWTF, LS14-031). JHA was supported by the Medical-Scientific fund of the Mayor of the federal capital Vienna [grant Covid003]. C.B. and A.B. were supported by ERC Starting Grants (European Union’s Horizon 2020 research and innovation program, grant agreement numbers 679146 respectively 677006). This project was funded in part by the Vienna Science and Technology Fund (WWTF) as part of the WWTF COVID-19 Rapid Response Funding 2020 (A.B.). We declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<p>Raw BAM files were submitted for inclusion in the COVID-19 Data Portal hosted by the European Bioinformatics Institute under project number PRJEB39849. Virus sequences are deposited in the GISAID database.</p>
</ack>
<ref-list>
<ref id="R1">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alcami</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Koszinowski</surname>
<given-names>UH</given-names>
</name>
</person-group>
<article-title>Viral mechanisms of immune evasion</article-title>
<source>Trends Microbiol</source>
<year>2000</year>
</element-citation>
</ref>
<ref id="R2">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Altmann</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Boyton</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection</article-title>
<source>Sci Immunol</source>
<year>2020</year>
<volume>5</volume>
<fpage>eabd6160</fpage>
</element-citation>
</ref>
<ref id="R3">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Le Bert</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Kunasegaran</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tham</surname>
<given-names>CYL</given-names>
</name>
<name>
<surname>Hafezi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chng</surname>
<given-names>MHY</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Linster</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls</article-title>
<source>Nature</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R4">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blaha</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Yoakum</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Hager</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Zha</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Gajewski</surname>
<given-names>TF</given-names>
</name>
<name>
<surname>Kranz</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>High-throughput stability screening of neoantigen/HLA complexes improves immunogenicity predictions</article-title>
<source>Cancer Immunol Res</source>
<year>2019</year>
<volume>7</volume>
<fpage>50</fpage>
<lpage>61</lpage>
</element-citation>
</ref>
<ref id="R5">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braun</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Loyal</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Frentsch</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wendisch</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Georg</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kurth</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hippenstiel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dingeldey</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kruse</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Fauchere</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19</article-title>
<source>Nature</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R6">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corbett</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Leist</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Abiona</surname>
<given-names>OM</given-names>
</name>
<name>
<surname>Boyoglu-Barnum</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gillespie</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Himansu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schäfer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ziwawo</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>DiPiazza</surname>
<given-names>AT</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness</article-title>
<source>Nature</source>
<year>2020</year>
<volume>586</volume>
<fpage>567</fpage>
<lpage>571</lpage>
</element-citation>
</ref>
<ref id="R7">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cox</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Mosbruger</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>XH</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Sidney</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sette</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pardoll</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>DL</given-names>
</name>
<etal/>
</person-group>
<article-title>Cellular immune selection with hepatitis C virus persistence in humans</article-title>
<source>J Exp Med</source>
<year>2005</year>
<volume>201</volume>
<fpage>1741</fpage>
<lpage>1752</lpage>
</element-citation>
</ref>
<ref id="R8">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dan</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Mateus</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hastie</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Faliti</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Ramirez</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Frazier</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Grifoni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rawlings</surname>
<given-names>SA</given-names>
</name>
<etal/>
</person-group>
<article-title>Immunological memory to SARS-CoV-2 assessed for greater than six months after infection</article-title>
<source>BioRxiv</source>
<year>2020</year>
<comment>2020.11.15.383323</comment>
</element-citation>
</ref>
<ref id="R9">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Pertea</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rongvaux</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Durand</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Ghiaur</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>J</given-names>
</name>
<name>
<surname>McHugh</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>
<article-title>Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations</article-title>
<source>Nature</source>
<year>2015</year>
<volume>517</volume>
<fpage>381</fpage>
<lpage>385</lpage>
</element-citation>
</ref>
<ref id="R10">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elbe</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Buckland-Merrett</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Data, disease and diplomacy: GISAID’s innovative contribution to global health</article-title>
<source>Glob Challenges</source>
<year>2017</year>
<volume>1</volume>
<fpage>33</fpage>
<lpage>46</lpage>
</element-citation>
</ref>
<ref id="R11">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez-Galarza</surname>
<given-names>FF</given-names>
</name>
<name>
<surname>McCabe</surname>
<given-names>A</given-names>
</name>
<name>
<surname>dos Santos</surname>
<given-names>EJM</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Takeshita</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ortega-Rivera</surname>
<given-names>ND</given-names>
</name>
<name>
<surname>Del Cid-Pavon</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Ramsbottom</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ghattaoraya</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Alfirevic</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools</article-title>
<source>Nucleic Acids Res</source>
<year>2019</year>
<volume>48</volume>
<fpage>D783</fpage>
<lpage>D788</lpage>
</element-citation>
</ref>
<ref id="R12">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goulder</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Watkins</surname>
<given-names>DI</given-names>
</name>
</person-group>
<article-title>Impact of MHC class I diversity on immune control of immunodeficiency virus replication</article-title>
<source>Nat Rev Immunol</source>
<year>2008</year>
<volume>8</volume>
<fpage>619</fpage>
<lpage>630</lpage>
</element-citation>
</ref>
<ref id="R13">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goulder</surname>
<given-names>PJR</given-names>
</name>
<name>
<surname>Watkins</surname>
<given-names>DI</given-names>
</name>
</person-group>
<article-title>HIV and SIV CTL escape: Implications for vaccine design</article-title>
<source>Nat Rev Immunol</source>
<year>2004</year>
</element-citation>
</ref>
<ref id="R14">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goulder</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Brander</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tremblay</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Colbert</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Addo</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Rosenberg</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Trocha</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Evolution and transmission of stable CTL escape mutations in HIV infection</article-title>
<source>Nature</source>
<year>2001</year>
<volume>412</volume>
<fpage>334</fpage>
<lpage>338</lpage>
</element-citation>
</ref>
<ref id="R15">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grifoni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Weiskopf</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ramirez</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Mateus</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dan</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Moderbacher</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Rawlings</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Sutherland</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Premkumar</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jadi</surname>
<given-names>RS</given-names>
</name>
<etal/>
</person-group>
<article-title>Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals</article-title>
<source>Cell</source>
<year>2020a</year>
<volume>181</volume>
<fpage>1489</fpage>
<lpage>1501 e15</lpage>
</element-citation>
</ref>
<ref id="R16">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grifoni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sidney</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Scheuermann</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sette</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2</article-title>
<source>Cell Host Microbe</source>
<year>2020b</year>
</element-citation>
</ref>
<ref id="R17">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hansen</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Bouvier</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>MHC class i antigen presentation: Learning from viral evasion strategies</article-title>
<source>Nat Rev Immunol</source>
<year>2009</year>
</element-citation>
</ref>
<ref id="R18">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hodcroft</surname>
<given-names>EB</given-names>
</name>
<name>
<surname>Zuber</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nadeau</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Comas</surname>
<given-names>I</given-names>
</name>
<name>
<surname>González Candelas</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Consortium</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Stadler</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Neher</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Emergence and spread of a SARS-CoV-2 variant through Europe in the summer of 2020</article-title>
<source>MedRxiv</source>
<year>2020</year>
<volume>2020</volume>
<comment>2020.10.25.20219063</comment>
</element-citation>
</ref>
<ref id="R19">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gifford</surname>
<given-names>DK</given-names>
</name>
</person-group>
<article-title>Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and their Augmentation by Compact Peptide Sets</article-title>
<source>BioRxiv</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R20">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mathew</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Giles</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Baxter</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Oldridge</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Greenplate</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Alanio</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kuri-Cervantes</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pampena</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>D’Andrea</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>
<article-title>Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications</article-title>
<source>Science (80-.)</source>
<year>2020</year>
<volume>369</volume>
<fpage>eabc8511</fpage>
</element-citation>
</ref>
<ref id="R21">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nelde</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bilich</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Heitmann</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Maringer</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Salih</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Roerden</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lübke</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rieth</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wacker</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition</article-title>
<source>Nat Immunol</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R22">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pircher</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Moskophidis</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rohrer</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Burki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hengartner</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zinkernagel</surname>
<given-names>RM</given-names>
</name>
</person-group>
<article-title>Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo</article-title>
<source>Nature</source>
<year>1990</year>
<volume>346</volume>
<fpage>629</fpage>
<lpage>633</lpage>
</element-citation>
</ref>
<ref id="R23">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Popa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Genger</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Nicholson</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Penz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Schmid</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Aberle</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Agerer</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lercher</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Endler</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Colaço</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>
<article-title>Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2</article-title>
<source>Sci Transl Med</source>
<year>2020</year>
<comment>eabe2555</comment>
</element-citation>
</ref>
<ref id="R24">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poran</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Harjanto</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Malloy</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Arieta</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Rothenberg</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Lenkala</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Van Buuren</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Addona</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Rooney</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Srinivasan</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Sequence-based prediction of SARS-CoV-2 vaccine targets using a mass spectrometry-based bioinformatics predictor identifies immunogenic T cell epitopes</article-title>
<source>Genome Med</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R25">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reynisson</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Alvarez</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Paul</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data</article-title>
<source>Nucleic Acids Res</source>
<year>2020</year>
<volume>48</volume>
<fpage>W449</fpage>
<lpage>W454</lpage>
</element-citation>
</ref>
<ref id="R26">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sahin</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Muik</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Derhovanessian</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vogler</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kranz</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Vormehr</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Baum</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pascal</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Quandt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Maurus</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses</article-title>
<source>Nature</source>
<year>2020</year>
<volume>586</volume>
<fpage>594</fpage>
<lpage>599</lpage>
</element-citation>
</ref>
<ref id="R27">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmitz</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Kuroda</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Santra</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sasseville</surname>
<given-names>VG</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Lifton</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Racz</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Tenner-Racz</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Dalesandro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Scallon</surname>
<given-names>BJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes</article-title>
<source>Science (80-.)</source>
<year>1999</year>
<volume>283</volume>
<fpage>857</fpage>
<lpage>860</lpage>
</element-citation>
</ref>
<ref id="R28">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schulien</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kemming</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Oberhardt</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Wild</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Seidel</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Killmer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sagar Daul</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Salvat Lago</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Decker</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells</article-title>
<source>Nat Med</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R29">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sekine</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Perez-Potti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rivera-Ballesteros</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Strålin</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gorin</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Olsson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Llewellyn-Lacey</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kamal</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bogdanovic</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Muschiol</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19</article-title>
<source>Cell</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R30">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shomuradova</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Vagida</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Sheetikov</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Zornikova</surname>
<given-names>KV</given-names>
</name>
<name>
<surname>Kiryukhin</surname>
<given-names>DD</given-names>
</name>
<name>
<surname>Titov</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Peshkova</surname>
<given-names>IO</given-names>
</name>
<name>
<surname>Khmelevskaya</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dianov</surname>
<given-names>DV</given-names>
</name>
<name>
<surname>Malasheva</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>SARSCoV-2 epitopes are recognized by a public and diverse repertoire of human T-cell receptors</article-title>
<source>Medrxiv</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R31">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thimme</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wieland</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Steiger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ghrayeb</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Reimann</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Purcell</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Chisari</surname>
<given-names>FV</given-names>
</name>
</person-group>
<article-title>CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection</article-title>
<source>J Virol</source>
<year>2003</year>
<volume>77</volume>
<fpage>68</fpage>
<lpage>76</lpage>
</element-citation>
</ref>
<ref id="R32">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vabret</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Britton</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Gruber</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hegde</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kuksin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Levantovsky</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Malle</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Moreira</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>MD</given-names>
</name>
<etal/>
</person-group>
<article-title>Immunology of COVID-19: current state of the science</article-title>
<source>Immunity</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R33">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ling</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Viral and host factors related to the clinical outcome of COVID-19</article-title>
<source>Nature</source>
<year>2020a</year>
</element-citation>
</ref>
<ref id="R34">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>The ORF8 Protein of SARS-CoV-2 Mediates Immune Evasion through Potently Downregulating MHC-I</article-title>
<source>BioRxiv</source>
<year>2020b</year>
<comment>2020.05.24.111823</comment>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Fig. 1</label>
<caption>
<p>Non-synonymous mutations are detected in SARS-CoV-2 CTL epitopes. <bold>A)</bold> Allele frequency of low-frequency mutations detected in 27 CTL epitopes. Epitopes are indicated on the right. The heatmap to the left indicates change in binding ranks predicted by netMHC-pan 4.1 (<xref ref-type="bibr" rid="R25">Reynisson et al., 2020</xref>). Barplots below the heatmap indicate viral loads as Ct values. <bold>B)</bold> Allele frequency of mutations in specified epitopes. Regions present in two epitopes are depicted separately. <bold>C)</bold> Frequency of global fixed mutations in CTL epitopes. <bold>D)</bold> Venn diagram depicting overlap between global fixed mutations and low frequency variants <bold>E)</bold> Mutations in CTL epitopes arise late in infection. Mutation frequency over time of two patients which were longitudinally sampled. Shown are variants that lead to non-synonymous mutations in CTL epitopes.</p>
</caption>
<graphic xlink:href="EMS108874-f001"/>
</fig>
<fig id="F2" position="float">
<label>Fig. 2</label>
<caption>
<p>Epitope variants lead to diminished MHC-1 binding. <bold>A-E</bold>) Decreased thermostability of mutant peptide MHC-I complexes. Negative first derivative of relative fluorescence units (rfu) plotted against increasing temperatures. Curves for wildtype peptides are black, mutated peptides are colored. The minimum point of the curves represents the melting temperature of peptide-MHC-I complexes. <bold>F)</bold> Tetramers featuring mutated peptides are instable at 37°C. FACS plots showing staining of in vitro expanded PBMCs stained with tetramers containing wildtype (top) or mutant (bottom) peptides incubated at 4°C (blue) or 37°C (red).</p>
</caption>
<graphic xlink:href="EMS108874-f002"/>
</fig>
<fig id="F3" position="float">
<label>Fig. 3</label>
<caption>
<p>SARS-CoV-2 epitope mutations lead to escape from CTL responses. <bold>A)</bold> Experimental overview. <bold>B)</bold> CTL responses against wildtype epitopes. PBMCs were isolated from HLAA*02:01 or HLA-B*40:01 positive SARS-CoV-2 patients, expanded 10-12 days with indicated peptides and stained with wildtype tetramers. <bold>C-E)</bold> T-cells expanded with mutant peptides do not give rise to wildtype peptide-specific PBMCs. PBMCs were isolated as in B), stimulated with wildtype or mutant peptides and stained with tetramers containing the wildtype peptide. <bold>F)</bold> Representative FACS plots for C-E. <bold>G-I)</bold> Impact of mutations on CTL cell response. PBMCs expanded with wildtype or mutant peptides as indicated, were analyzed for IFNγ-production via intracellular cytokine staining after restimulation with each peptide (n = 3-13 patients per epitope). <bold>J)</bold> Representative FACS plots for D-F. <bold>K)</bold> <italic>Ex vivo</italic> IFNγ ELISpot assays from PBMCs stimulated with the YLQ peptide or the corresponding mutant. (N=6) or the MEV peptide and corresponding mutant (N=1), shown are results from one repesentative patient for stimulation with the YLQ peptide. Significance is indicated as *<italic>P</italic>&lt;0.05, **<italic>P</italic>&lt;0.01, ***<italic>P</italic>&lt;0.001, ****<italic>P</italic>&lt;0.0001, tested by Wilcoxon matched-pairs signed rank test</p>
</caption>
<graphic xlink:href="EMS108874-f003"/>
</fig>
</floats-group>
</article>
